Amgen vs. Vertex Pharmaceuticals: Value Stability vs. High-Growth Biotech Investment Plays Sep 14, 2026 Life Science
Johnson & Johnson Advances Spin-Off and Sale in Parallel as Orthopedics Business Valued at Nearly $20 Billion Sep 11, 2026 Life Science
Novo Nordisk Scores Pediatric Weight-Loss Trial Win, Unlocking Contrarian Investment Value Sep 11, 2026 Life Science
From $275 to $461, UnitedHealth Regains Confidence Through a Turnaround Script Sep 9, 2026 Life Science
AbbVie’s Diversification Bet Gradually Shows Results, While Pfizer Seeks a Second Takeoff Through Its GLP-1 and Oncology Pipelines Sep 5, 2026 Life Science
Pfizer Trades Below 10x P/E, But Does That Signal a Value Trap or a Long-Term Opportunity? Sep 4, 2026 Life Science
Eli Lilly Swallows Merida, Expanding Pipeline with Another Strategic Acquisition Sep 3, 2026 Life Science
Gene-Editing Pioneer CRISPR Therapeutics Worth a Bet Before Year-End? Two Catalysts Await Release Sep 3, 2026 Life Science
GLP-1 Concept Stock Amylyx Soars 247% Year-to-Date: How Much Room Remains for Upside? Sep 2, 2026 Life Science
Ark Invest Goes Against the Grain: Wood Bets on Nvidia and the Gene-Editing Arena Sep 1, 2026 Life Science
Eli Lilly Is on an M&A Spree—Will the $2.88 Billion Merida Deal Be Enough to Diversify? Aug 31, 2026 Life Science
